CCT6A is associated with CDC20, Enneking stage and prognosis in osteosarcoma, and its knockdown suppresses osteosarcoma cell viability and invasion

Wang,Ning; Chen,Yong; Wu,Jie

doi:10.3892/ol.2023.13787

CCT6A is associated with CDC20, Enneking stage and prognosis in osteosarcoma, and its knockdown suppresses osteosarcoma cell viability and invasion

Authors:
- Ning Wang
- Yong Chen
- Jie Wu
View Affiliations

Affiliations: Department of Orthopedics, Center Hospital Affiliated to Shenyang Medical College, Shenyang, Liaoning 110024, P.R. China, Department of Hand Surgery, Center Hospital Affiliated to Shenyang Medical College, Shenyang, Liaoning 110024, P.R. China
Published online on: April 4, 2023 https://doi.org/10.3892/ol.2023.13787
Article Number: 201
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chaperonin‑containing tailless complex polypeptide 1 subunit 6A (CCT6A) regulates the proliferation, invasiveness and stemness of numerous types of cancer, and may interact with cell division cycle 20 (CDC20); however, its implication in osteosarcoma remains unclear. The present study aimed to investigate the relationship between CCT6A and CDC20, and their association with clinical features and prognosis. Subsequently, the present study explored the effects of their knockdown on osteosarcoma cell malignant behaviors. A total of 52 patients with osteosarcoma underwent tumor resection were retrospectively analyzed. CCT6A and CDC20 expression levels in tumor and nontumor tissues were detected by reverse transcription‑quantitative PCR and immunohistochemistry. In addition, CCT6A and CDC20 small interfering RNA molecules were transfected into osteosarcoma cell lines. The results revealed that the mRNA (P<0.001) and protein (P<0.001) expression levels of CCT6A were elevated in tumor tissues compared with those in nontumor tissues. Tumor CCT6A mRNA expression was correlated with elevated CDC20 mRNA expression (P<0.001), higher Enneking stage (P=0.039), abnormal lactate dehydrogenase (LDH) level (>300 U/l) (P=0.048), lower pathological response (P=0.024) and worse disease‑free survival (DFS) (P=0.015). Tumor CCT6A protein expression was also associated with increased CDC20 protein (P<0.001), elevated Enneking stage (P=0.005), abnormal LDH (P=0.019), decreased pathological response (P=0.014), shorter DFS (P=0.030) and overall survival (OS) (P=0.027). After adjustment by multivariate Cox analyses, tumor CCT6A mRNA expression was shown to independently predict lower pathological response (P=0.033) and poor DFS (P=0.028), but not OS. Regarding CDC20, it was associated with a higher Enneking stage and lower pathological response (both P<0.05), whereas it failed to estimate DFS or OS. In vitro experiments demonstrated that CCT6A and CDC20 knockdown inhibited proliferation and invasion, and enhanced apoptosis in U‑2 OS and Saos‑2 cells (all P<0.05). In conclusion, CCT6A is associated with CDC20, Enneking stage and prognosis of osteosarcoma, and its knockdown decreases the viability and invasion of osteosarcoma cells.

View Figures

View References

1	Prater S and McKeon B: Osteosarcoma. StatPearls. StatPearls Publishing; Treasure Island, FL: 2022
2	Sadykova LR, Ntekim AI, Muyangwa-Semenova M, Rutland CS, Jeyapalan JN, Blatt N and Rizvanov AA: Epidemiology and risk factors of osteosarcoma. Cancer Invest. 38:259–269. 2020. View Article : Google Scholar : PubMed/NCBI
3	de Azevedo JWV, de Medeiros Fernandes TAA, Fernandes JV Jr, de Azevedo JCV, Lanza DCF, Bezerra CM, Andrade VS, de Araújo JMG and Fernandes JV: Biology and pathogenesis of human osteosarcoma. Oncol Lett. 19:1099–1116. 2020.PubMed/NCBI
4	Czarnecka AM, Synoradzki K, Firlej W, Bartnik E, Sobczuk P, Fiedorowicz M, Grieb P and Rutkowski P: Molecular biology of osteosarcoma. Cancers (Basel). 12:21302020. View Article : Google Scholar : PubMed/NCBI
5	Chen B, Zeng Y, Liu B, Lu G, Xiang Z, Chen J, Yu Y, Zuo Z, Lin Y and Ma J: Risk factors, prognostic factors, and nomograms for distant metastasis in patients with newly diagnosed osteosarcoma: A population-based study. Front Endocrinol (Lausanne). 12:6720242021. View Article : Google Scholar : PubMed/NCBI
6	Jafari F, Javdansirat S, Sanaie S, Naseri A, Shamekh A, Rostamzadeh D and Dolati S: Osteosarcoma: A comprehensive review of management and treatment strategies. Ann Diagn Pathol. 49:1516542020. View Article : Google Scholar : PubMed/NCBI
7	Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, et al: Survival and prognosis with osteosarcoma: Outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 109:36–50. 2019. View Article : Google Scholar : PubMed/NCBI
8	Xiao B, Liu L, Li A, Xiang C, Wang P, Li H and Xiao T: Identification and verification of immune-related gene prognostic signature based on ssGSEA for osteosarcoma. Front Oncol. 10:6076222020. View Article : Google Scholar : PubMed/NCBI
9	Smrke A, Anderson PM, Gulia A, Gennatas S, Huang PH and Jones RL: Future directions in the treatment of osteosarcoma. Cells. 10:1722021. View Article : Google Scholar : PubMed/NCBI
10	Zeng G, Wang J and Huang Y, Lian Y, Chen D, Wei H, Lin C and Huang Y: Overexpressing CCT6A contributes to cancer cell growth by affecting the G1-To-S phase transition and predicts A negative prognosis in hepatocellular carcinoma. Onco Targets Ther. 12:10427–10439. 2019. View Article : Google Scholar : PubMed/NCBI
11	Yang X, Tong Y, Ye W and Chen L: HOXB2 increases the proliferation and invasiveness of colon cancer cells through the upregulation of CCT6A. Mol Med Rep. 25:1742022. View Article : Google Scholar : PubMed/NCBI
12	Li B, Lu X, Ma C, Sun S, Shu X, Wang Z and Sun W: Long non-coding RNA NEAT1 promotes human glioma tumor progression via miR-152-3p/CCT6A pathway. Neurosci Lett. 732:1350862020. View Article : Google Scholar : PubMed/NCBI
13	Peng X, Chen G, Lv B and Lv J: MicroRNA-148a/152 cluster restrains tumor stem cell phenotype of colon cancer via modulating CCT6A. Anticancer Drugs. 33:e610–e621. 2022. View Article : Google Scholar : PubMed/NCBI
14	Wang H, Wang X, Xu L, Lin Y and Zhang J: CCT6A and CHCHD2 are coamplified with EGFR and associated with the unfavorable clinical outcomes of lung adenocarcinoma. Dis Markers. 2022:15601992022.PubMed/NCBI
15	He T, Yu D, Wang Z, Guo C, Chang Y and Wang D: Chaperonin-containing tailless complex polypeptide 1 subunit 6A links with aggravating tumor features and disease-free survival in surgical gastric cancer patients: A long-term follow-up study. Clin Res Hepatol Gastroenterol. 46:1019132022. View Article : Google Scholar : PubMed/NCBI
16	Peng W, Li W, Zhang X, Cen W and Liu Y: The intercorrelation among CCT6A, CDC20, CCNB1, and PLK1 expressions and their clinical value in papillary thyroid carcinoma prognostication. J Clin Lab Anal. 36:e246092022. View Article : Google Scholar : PubMed/NCBI
17	Volonte D, Sedorovitz M and Galbiati F: Impaired Cdc20 signaling promotes senescence in normal cells and apoptosis in non-small cell lung cancer cells. J Biol Chem. 298:1024052022. View Article : Google Scholar : PubMed/NCBI
18	Greil C, Engelhardt M and Wäsch R: The role of the APC/C and its coactivators Cdh1 and Cdc20 in cancer development and therapy. Front Genet. 13:9415652022. View Article : Google Scholar : PubMed/NCBI
19	Ni K and Hong L: Current progress and perspectives of CDC20 in female reproductive cancers. Curr Mol Med. 23:193–199. 2023. View Article : Google Scholar : PubMed/NCBI
20	Wang H, Liu Z, Wu P, Wang H and Ren W: NUSAP1 Accelerates osteosarcoma cell proliferation and cell cycle progression via upregulating CDC20 and cyclin A2. Onco Targets Ther. 14:3443–3454. 2021. View Article : Google Scholar : PubMed/NCBI
21	Gao Y, Guo C, Fu S, Cheng Y and Song C: Downregulation of CDC20 suppressed cell proliferation, induced apoptosis, triggered cell cycle arrest in osteosarcoma cells, and enhanced chemosensitivity to cisplatin. Neoplasma. 68:382–390. 2021. View Article : Google Scholar : PubMed/NCBI
22	Zeng W, Wu M, Cheng Y, Liu L, Han Y, Xie Q, Li J, Wei L, Fang Y, Chen Y, et al: CCT6A knockdown suppresses osteosarcoma cell growth and Akt pathway activation in vitro. PLoS One. 17:e02798512022. View Article : Google Scholar : PubMed/NCBI
23	Enneking WF, Spanier SS and Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 106–120. 1980.PubMed/NCBI
24	Qiao S, Qi K, Liu C, Xu C, Ma J, Xu X, Li C and Wang Z: Long intergenic non-coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo. J Clin Lab Anal. 34:e231642020. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Wu MS, Ma QY, Liu DD, Li XJ, Deng LJ, Li N, Shen J, Zhao Z and Chen JX: CDC20 and its downstream genes: Potential prognosis factors of osteosarcoma. Int J Clin Oncol. 24:1479–1489. 2019. View Article : Google Scholar : PubMed/NCBI
27	Ma J, Yang L, Feng H, Zheng L, Meng H and Li X: CCT6A may act as a potential biomarker reflecting tumor size, lymphatic metastasis, FIGO stage, and prognosis in cervical cancer patients. J Clin Lab Anal. 35:e237932021. View Article : Google Scholar : PubMed/NCBI
28	Huvos AG and Higinbotham NL: Primary fibrosarcoma of bone. A clinicopathologic study of 130 patients. Cancer. 35:837–847. 1975. View Article : Google Scholar : PubMed/NCBI
29	Cai Y, Wu D and Zhan L: CCT6A expression in hepatocellular carcinoma and its correlation with clinical characteristics, liver function indexes, tumor markers and prognosis. Clin Res Hepatol Gastroenterol. 46:1017962022. View Article : Google Scholar : PubMed/NCBI
30	Jiang J, Liu C, Xu G, Liang T, Yu C, Liao S, Zhang Z, Lu Z, Wang Z, Chen J, et al: CCT6A, a novel prognostic biomarker for Ewing sarcoma. Medicine (Baltimore). 100:e244842021. View Article : Google Scholar : PubMed/NCBI
31	Zhang X, Zhang X, Li X, Bao H, Li G, Li N, Li H and Dou J: Connection between CDC20 expression and hepatocellular carcinoma prognosis. Med Sci Monit. 27:e9267602021.PubMed/NCBI
32	Gayyed MF, El-Maqsoud NM, Tawfiek ER, El Gelany SA and Rahman MF: A comprehensive analysis of CDC20 overexpression in common malignant tumors from multiple organs: Its correlation with tumor grade and stage. Tumour Biol. 37:749–762. 2016. View Article : Google Scholar : PubMed/NCBI
33	Gao Y, Zhang B, Wang Y and Shang G: Cdc20 inhibitor apcin inhibits the growth and invasion of osteosarcoma cells. Oncol Rep. 40:841–848. 2018.PubMed/NCBI
34	Evenhuis RE, Acem I, Rueten-Budde AJ, Karis DSA, Fiocco M, Dorleijn DMJ, Speetjens FM, Anninga J, Gelderblom H and van de Sande MAJ: Survival analysis of 3 different age groups and prognostic factors among 402 patients with skeletal high-grade osteosarcoma. Real world data from a single tertiary sarcoma center. Cancers (Basel). 13:4862021. View Article : Google Scholar : PubMed/NCBI